arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Tango Therapeutics, Inc.

TNGX

$27.07 ▼ -1.92 (-6.62%) at close

7 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Tango Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.1B

Dividend Yield —

Revenue Growth 48.3% ↗

Op. Margin -178.4% ↗

ROIC -32.1% ↗

FCF / Share $-1.20 →

Trailing P/E —

Price / Book 10.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$62.38M

↑ +48.3% —

Net Income Profit after all expenses

$-101.59M

↑ +22.0% —

Operating Margin Operating profit as % of sales

-178.4%

↑ +48.5% 1th

FCF / Share Free cash flow per share

$-1.20

↑ +0.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	48.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+504%)	15.2% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+90%)	46.9% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+487%)	-32.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-511%)	383.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4698%)	—	—
EPS Growth YoY (%)	26.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-10.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	12.2% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-30.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	22.0% Good ↑ Good Improving Year-over-year change in net income	-28.1% Weak ↑ Weak Improving Year-over-year change in net income	5.9% Fair ↑ Fair Improving Year-over-year change in net income	-85.8% Weak Weak Year-over-year change in net income	-12.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	0.5% Caution ↑ Caution Improving Year-over-year change in free cash flow	4.2% Caution ↑ Caution Improving Year-over-year change in free cash flow	5.0% Caution Caution Year-over-year change in free cash flow	-34.6% Weak Weak Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	35.9% Excellent → Excellent Stable Compound annual revenue growth over 3 years	4.3% Caution Caution Compound annual revenue growth over 3 years	68.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	52.1% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-178.4% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1289%)	-346.1% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2407%)	-312.6% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2184%)	-446.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3079%)	-157.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1147%)	—	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-162.9% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1457%)	-309.7% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2681%)	-278.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2421%)	-435.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3726%)	-157.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1410%)	—	—
FCF Margin (%) (%)	-224.3% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-314.4% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-327.2% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-469.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-165.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	1.38x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	-1.33x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-32.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-73.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-44.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-135.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-27.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-46.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-25.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-29.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-296%)	-65.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-535%)	-40.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-368%)	-43.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-389%)	-16.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-213%)	-134.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-998%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-112.28M	$-69.53M	$-66.39M	$-59.97M	$-142.75M	$-28.38M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.54	$0.39	$0.39	$0.28	$0.60	—	—
Basic EPS, GAAP (USD)	$-0.87	$-1.19	$-1.08	$-1.23	$-0.94	—	—
Free Cash Flow per Share (USD)	$-1.20	$-1.21	$-1.26	$-1.33	$-0.99	—	—
Book Value per Share (USD)	$2.55	$1.85	$2.48	$2.83	$3.94	$0.96	—
Tangible Book Value per Share (USD)	$2.55	$1.85	$2.48	$2.83	$3.94	$0.96	—
Basic Weighted Avg Shares (shares)	116.17M	109.23M	94.57M	87.82M	62.11M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$332.08M	$228.17M	$300.60M	$319.73M	$451.65M	$152.72M	—
Total Equity (USD)	$346.18M	$199.52M	$253.11M	$249.48M	$344.75M	$38.60M	$7.91M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$62.38M	$42.07M	$36.53M	$24.86M	$37.04M	$7.66M	—
Depreciation Expense (USD)	$2.28M	$2.50M	$2.42M	$1.61M	$897.00K	$718.00K	—
Net Income, GAAP (USD)	$-101.59M	$-130.30M	$-101.74M	$-108.18M	$-58.23M	$-51.97M	—
Operating Cash Flow (USD)	$-138.89M	$-131.50M	$-117.98M	$-109.08M	$-59.53M	$70.07M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Tango Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TNGX with peers